307 related articles for article (PubMed ID: 19376384)
1. Sirolimus in pediatric liver transplantation: a single-center experience.
Gibelli NE; Tannuri U; Pinho-Apezzato ML; Tannuri AC; Maksoud-Filho JG; Andrade WC; Velhote MC; Santos MM; Ayoub AA; Marques da Silva M
Transplant Proc; 2009 Apr; 41(3):901-3. PubMed ID: 19376384
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma.
Jiménez-Rivera C; Avitzur Y; Fecteau AH; Jones N; Grant D; Ng VL
Pediatr Transplant; 2004 Jun; 8(3):243-8. PubMed ID: 15176961
[TBL] [Abstract][Full Text] [Related]
3. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
[TBL] [Abstract][Full Text] [Related]
4. Liver transplantation at the University of Chicago.
Millis JM; Alonso EM; Piper JB; Bruce DS; Newell KA; Woodle ES; Baker AL; Whitington PF; Thistlethwaite JR
Clin Transpl; 1995; ():187-97. PubMed ID: 8794265
[TBL] [Abstract][Full Text] [Related]
5. Proteinuria after conversion to sirolimus in renal transplant recipients.
Sahin GM; Sahin S; Kantarci G; Ergin H
Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
[TBL] [Abstract][Full Text] [Related]
6. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus.
Casas-Melley AT; Falkenstein KP; Flynn LM; Ziegler VL; Dunn SP
Pediatr Transplant; 2004 Aug; 8(4):362-6. PubMed ID: 15265163
[TBL] [Abstract][Full Text] [Related]
7. Conversion to sirolimus in pediatric renal transplantation recipients.
Garcia CD; Bittencourt VB; Alves AB; Garcia VD; Tumelero A; Antonello JS; Malheiros D
Transplant Proc; 2006; 38(6):1901-3. PubMed ID: 16908317
[TBL] [Abstract][Full Text] [Related]
8. Replacing calcineurin inhibitors with mTOR inhibitors in children.
Sindhi R; Seward J; Mazariegos G; Soltys K; Seward L; Smith A; Kosmach B; Venkataramanan R
Pediatr Transplant; 2005 Jun; 9(3):391-7. PubMed ID: 15910398
[TBL] [Abstract][Full Text] [Related]
9. Primary immunosuppression regimen of rapid steroid withdrawal after living related liver transplantation: a single-center experience.
Toyoki Y; Hakamada K; Narumi S; Totsuka E; Nara M; Ono H; Ishizawa Y; Sasaki M
Transplant Proc; 2004 Oct; 36(8):2279-81. PubMed ID: 15561218
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus in pediatric renal transplantation.
Ibáñez JP; Monteverde ML; Goldberg J; Diaz MA; Turconi A
Transplant Proc; 2005 Mar; 37(2):682-4. PubMed ID: 15848500
[TBL] [Abstract][Full Text] [Related]
11. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases.
Baccarani U; Adani GL; Montanaro D; Risaliti A; Lorenzin D; Avellini C; Tulissi P; Groppuzzo M; Currò G; Luvisetto F; Beltrami A; Bresadola V; Viale PL; Bresadola F
Transplant Proc; 2006 May; 38(4):1135-7. PubMed ID: 16757287
[TBL] [Abstract][Full Text] [Related]
12. Nephrotoxic effects of immunosuppressant therapy in pediatric liver transplant recipients.
McCulloch MI; Burger H; Spearman CW; Cooke L; Goddard E; Gajjar P; Numanoglu A; Rode H; Kahn D; Millar AJ
Transplant Proc; 2005 Mar; 37(2):1220-3. PubMed ID: 15848675
[TBL] [Abstract][Full Text] [Related]
13. The role and value of sirolimus administration in kidney and liver transplantation.
Mehrabi A; Fonouni H; Kashfi A; Schmied BM; Morath Ch; Sadeghi M; Schemmer P; Encke J; Sauer P; Zeier M; Weitz J; Büchler MW; Schmidt J
Clin Transplant; 2006; 20 Suppl 17():30-43. PubMed ID: 17100699
[TBL] [Abstract][Full Text] [Related]
14. Dyslipidemia during sirolimus therapy in patients after liver transplantation.
Kniepeiss D; Iberer F; Schaffellner S; Jakoby E; Duller D; Tscheliessnigg Kh
Clin Transplant; 2004 Dec; 18(6):642-6. PubMed ID: 15516237
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus.
Sindhi R; Webber S; Venkataramanan R; McGhee W; Phillips S; Smith A; Baird C; Iurlano K; Mazariegos G; Cooperstone B; Holt DW; Zeevi A; Fung JJ; Reyes J
Transplantation; 2001 Sep; 72(5):851-5. PubMed ID: 11571449
[TBL] [Abstract][Full Text] [Related]
16. Pediatric liver transplantation: ten years of experience in a multicentric program in Chile.
Uribe M; Buckel E; Ferrario M; Godoy J; González G; Hunter B; Ceresa S; Cavallieri S; Berwart F; Herzog C; Santander MT; Calabrán L
Transplant Proc; 2005 Oct; 37(8):3375-7. PubMed ID: 16298599
[TBL] [Abstract][Full Text] [Related]
17. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center.
Quintini C; Kato T; Gaynor JJ; Ueno T; Selvaggi G; Gordon P; McLaughlin G; Tompson J; Ruiz P; Tzakis A
Transplant Proc; 2006; 38(6):1755-8. PubMed ID: 16908272
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus-related neurologic and renal complications in liver transplantation: A single-center experience.
Emiroglu R; Ayvaz I; Moray G; Karakayali H; Haberal M
Transplant Proc; 2006 Mar; 38(2):619-21. PubMed ID: 16549190
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival expectancy after liver transplantation in children.
Migliazza L; López Santamaría M; Murcia J; Gamez M; Clavijo J; Camarena C; Hierro L; Frauca E; de la Vega A; Diaz M; Jara P; Tovar JA
J Pediatr Surg; 2000 Jan; 35(1):5-7; discussion 7-8. PubMed ID: 10646764
[TBL] [Abstract][Full Text] [Related]
20. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy.
Al-Akash SI; Al Makadma AS; Al Omari MG
Pediatr Transplant; 2005 Apr; 9(2):249-53. PubMed ID: 15787802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
